<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) was examined in vitro in 23 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and 14 with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) to investigate the clinical use of rh-Ep for these diseases </plain></SENT>
<SENT sid="1" pm="."><plain>Bone marrow mononuclear cells were cultured by <z:chebi fb="0" ids="53448">methylcellulose</z:chebi> methods for CFU-E and BFU-E assays </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:mpath ids='MPATH_458'>normals</z:mpath>, the CFU-E numbers reached a plateau of increase at Ep doses of almost 2-5 units, and no further increase was observed with the addition of larger Ep doses </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, the responses of CFU-E to Ep were relatively good in nonsevere type and generally poor in severe type </plain></SENT>
<SENT sid="4" pm="."><plain>However, the CFU-E numbers increased with increasing doses of Ep in some of the patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Among the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, the responses of CFU-E to Ep were relatively good in primary acquired <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (<z:chebi fb="8" ids="28618">PARA</z:chebi>) and primary acquired <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>On the other hand, the responses of CFU-E to Ep were poor in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with an excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>BFU-E responses to Ep were poor in severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>However, there are Ep responsive patients in some of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:chebi fb="8" ids="28618">PARA</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>High titers of rh-Ep were suggested to be effective clinically in some patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and those with <z:chebi fb="8" ids="28618">PARA</z:chebi> </plain></SENT>
</text></document>